WO2007038754A3 - Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis - Google Patents

Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis Download PDF

Info

Publication number
WO2007038754A3
WO2007038754A3 PCT/US2006/038170 US2006038170W WO2007038754A3 WO 2007038754 A3 WO2007038754 A3 WO 2007038754A3 US 2006038170 W US2006038170 W US 2006038170W WO 2007038754 A3 WO2007038754 A3 WO 2007038754A3
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatoid arthritis
treatment
gene expression
expression profiling
identification monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/038170
Other languages
French (fr)
Other versions
WO2007038754A2 (en
Inventor
Danute Bankaitis-Davis
Kathy Storm
Lisa Siconolfi
David B Trollinger
Karl Wassmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOURCE MDX
Original Assignee
SOURCE MDX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOURCE MDX filed Critical SOURCE MDX
Priority to AU2006294477A priority Critical patent/AU2006294477A1/en
Priority to EP06836158A priority patent/EP1945814A2/en
Priority to CA002624359A priority patent/CA2624359A1/en
Publication of WO2007038754A2 publication Critical patent/WO2007038754A2/en
Publication of WO2007038754A3 publication Critical patent/WO2007038754A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method is provided in various embodiments for determining a profile data set for a subject with rheumatoid arthritis or inflammatory conditions related to rheumatoid arthritis based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 2 constituents from a gene panel. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.
PCT/US2006/038170 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis Ceased WO2007038754A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2006294477A AU2006294477A1 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
EP06836158A EP1945814A2 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
CA002624359A CA2624359A1 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72105205P 2005-09-27 2005-09-27
US60/721,052 2005-09-27

Publications (2)

Publication Number Publication Date
WO2007038754A2 WO2007038754A2 (en) 2007-04-05
WO2007038754A3 true WO2007038754A3 (en) 2007-07-26

Family

ID=37708412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038170 Ceased WO2007038754A2 (en) 2005-09-27 2006-09-27 Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis

Country Status (5)

Country Link
US (1) US7935482B2 (en)
EP (2) EP1945814A2 (en)
AU (1) AU2006294477A1 (en)
CA (1) CA2624359A1 (en)
WO (1) WO2007038754A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503206A (en) * 2004-05-25 2008-02-07 日立化成工業株式会社 How to measure cancer susceptibility
CN101044249B (en) * 2004-10-20 2012-09-05 日立化成工业株式会社 A method to customize drug delivery by quantifying mRNA
CA2589746A1 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
ATE512234T1 (en) * 2005-04-28 2011-06-15 Hitachi Chemical Res Ct Inc EX-VIVO GENE EXPRESSION IN WHOLE BLOOD AS A MODEL FOR ASSESSING INDIVIDUAL VARIATION AGAINST FOOD ADDITIVES
JP4800384B2 (en) 2005-06-08 2011-10-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド Methods for predicting immune responses against neoplastic diseases based on mRNA expression profiles in tumor cells and stimulated leukocytes
JP2009536021A (en) * 2006-04-07 2009-10-08 日立化成工業株式会社 Increased FC receptor-mediated tumor necrosis factor superfamily and chemokine mRNA expression in peripheral blood leukocytes of patients with rheumatoid arthritis
ATE518011T1 (en) * 2006-04-07 2011-08-15 Hitachi Chemical Co Ltd INCREASED EXPRESSION OF T-CELL RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH CROHN'S DISEASE
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
JP2011502535A (en) * 2007-11-14 2011-01-27 日立化成工業株式会社 Tumor necrosis factor superfamily mRNA expression through Fc receptors in peripheral blood leukocytes
EP2075343A1 (en) * 2007-12-21 2009-07-01 Gert Mayer A method of diagnosing a progressive disease
US20090215064A1 (en) * 2008-02-27 2009-08-27 Hitachi Chemical Co., Ltd. Quantitative assessment of individual cancer susceptibility by measuring dna damage-induced mrna in whole blood
WO2009155559A1 (en) * 2008-06-20 2009-12-23 Medimmune Llc Interferon alpha-induced pharmacodynamic markers
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
EP2440935B1 (en) * 2009-06-09 2017-08-09 Mayer, Gert A method of diagnosing renal disorders
JP5996429B2 (en) * 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド Method for treatment, diagnosis and monitoring of rheumatoid arthritis
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
CN102918165A (en) * 2010-03-24 2013-02-06 Tc园表达公司 Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (CYTD)
JP2013526852A (en) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Circulating biomarkers for disease
RU2012153786A (en) 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
KR20230109779A (en) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
DE112016003948T5 (en) 2015-08-31 2018-05-09 City Of Sapporo MOLECULAR METHODS FOR EVALUATING A UROTHIAL DISEASE
KR20240095481A (en) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Methods of diagnosing inflammatory bowel disease through rnaset2
US11480568B2 (en) * 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases
JP7496324B2 (en) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション Method and system for predicting responsiveness to anti-TNF therapy - Patent Application 20070123333
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
CA3180476A1 (en) * 2020-05-29 2021-12-02 Robert B. Darnell Markers and cellular antecedents of rheumatoid arthritis flares
GB202009689D0 (en) * 2020-06-25 2020-08-12 Univ Ulster A method of predicting response to treatment with a disease-modifying anti-rheumatic drug and/or classifying disease activity in a subject with rheumatoid art
WO2023097061A2 (en) * 2021-11-26 2023-06-01 The Rockefeller University Markers and cellular antecedents of rheumatoid arthritis flares
CN117717544A (en) * 2023-11-22 2024-03-19 中国人民解放军联勤保障部队第九二〇医院 Use of chrysin in the preparation of drugs for the treatment of rheumatoid arthritis
CN118186074A (en) * 2024-04-24 2024-06-14 华中科技大学同济医学院附属同济医院 Application of DPP4 as a marker and target for rheumatoid arthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
WO2004110244A2 (en) * 2003-05-08 2004-12-23 Vanderbilt University A gene equation to diagnose rheumatoid arthritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
WO1998024935A1 (en) 1996-12-06 1998-06-11 Urocor, Inc. Diagnosis of disease state using mrna profiles
CA2378008A1 (en) 1999-06-28 2001-04-12 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
WO2004110244A2 (en) * 2003-05-08 2004-12-23 Vanderbilt University A gene equation to diagnose rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOVIN LF ET AL.: "Blood cell gene expression profiling in rheumatoid arthritis - Discriminative genes and effect of rheumatoid factor", IMMUNOLOGY LETTERS, vol. 93, no. 2-3, 15 May 2004 (2004-05-15), pages 217 - 226, XP002419834 *

Also Published As

Publication number Publication date
US20070196835A1 (en) 2007-08-23
CA2624359A1 (en) 2007-04-05
EP1945814A2 (en) 2008-07-23
AU2006294477A1 (en) 2007-04-05
WO2007038754A2 (en) 2007-04-05
US7935482B2 (en) 2011-05-03
EP2161348A1 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
WO2007038754A3 (en) Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2008063414A3 (en) Gene expression profiling for identification, monitoring, and treatment of colorectal cancer
WO2008063413A3 (en) Gene expression profiling for identification, monitoring, and treatment of lung cancer
WO2008123866A3 (en) Gene expression profiling for identification, monitoring and treatment of ovarian cancer
WO2008069881A3 (en) Gene expression profiling for identification, monitoring and treatment of melanoma
WO2008121132A3 (en) Gene expression profiling for identification, monitoring, and treatment of prostate cancer
WO2008143639A3 (en) Gene expression profiling for identification, monitoring, and treatment of cervical cancer
WO2010006048A3 (en) Gene expression profiling for predicting the survivability of prostate cancer subjects
WO2010080702A3 (en) Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
WO2008082529A3 (en) Gene expression profiling for identification, monitoring, and treatment of ocular disease
WO2004099432A3 (en) Identification of biomarkers for detecting pancreatic cancer
ATE414166T1 (en) GLUCOSE BIOSENSOR AND METHOD
MX2010000971A (en) System and methods for determination of analyte concentration using time resolved amperometry.
TWI266042B (en) Method to determine the value of process parameters based on scatterometry data
EP2073691A4 (en) METHOD AND SYSTEM FOR DYNAMICALLY UPDATING CALIBRATION PARAMETERS OF A DETECTOR OF SUBSTANCES TO BE ANALYZED
DE60020119D1 (en) Method and device for investigating drug candidates and for determining their pharmacokinetic parameters
WO2009104016A3 (en) Methods of calibrating a sensor in a patient monitoring system
WO2003040728A3 (en) Method and apparatus for the determination of glucose
WO2006099151A3 (en) System and methods for processing analyte sensor data for sensor calibration
WO2005095644A3 (en) Method for recognizing signatures in complex gene expression profiles
WO2004012588A3 (en) Use of biomarkers for detecting ovarian cancer
WO2007061992A3 (en) Method and apparatus for background current arrangements for a biosensor
WO2007025044A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2008011158A3 (en) Method of detecting and/ or measuring hepcidin in a sample
ATE504044T1 (en) PARAMETRIC CALIBRATION PROCEDURE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2624359

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006294477

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006294477

Country of ref document: AU

Date of ref document: 20060927

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006836158

Country of ref document: EP